KLK3 and prostate cancer: The antitumor activityof compounds 41, 42, 45, 46, and 47 was evaluatedagainst prostate cancer resistant to AR-targeted therapy cell line22Rv1, which is an aggressive type of cancer with a low survival rate.All steroids exhibited moderate cytotoxic activity (emphasizing compound 47 with IC50 = 64.4 ± 14.9 μM) and wereable to inhibit the expression of a prostate-specific antigen, indicatingthat inhibition may occur via PSA.